<DOC>
	<DOCNO>NCT01015352</DOCNO>
	<brief_summary>The study aim treat low-risk MDS patient , dependent red-blood cell transfusion due disease-related anemia , proven resistance towards treatment erythropoetin-stimulating agent ( ESA ) . The study randomize patient receive treatment demethylating agent 5-azacytidine alone combination ESA . The study thus evaluate , efficacy 5-azacytidine , notably red-blood cell transfusion-dependence comparable/inferior combination treatment azacitidine ESA ( 5-azacytidine overcome resistance towards ESA ) . Being phase II study , study ass , duration erythroid response , overall survival time progression well toxicity .</brief_summary>
	<brief_title>Azacitidine Combined Epoetin Beta International Prognostic Scoring System ( IPSS ) Low-risk Intermediate-1 Myelodysplastic Syndrome ( MDS ) Patients , Resistant Erythropoetin-stimulating Agents ( ESA )</brief_title>
	<detailed_description>Phase II Study Azacitidine ( Vidaza® ) Combined Epoetin Beta ( NeoRecormon® ) IPSS Low-risk Intermediate-1 MDS Patients , Resistant ESA The Primary Endpoint study determine major erythroid response rate 6 course , assess accord IWG 2000 criterion . The Secondary Endpoints determine percentage major HI-E minor HI-E 4 6 course accord IWG 2000 , HI-E IWG 2006 criterion , duration erythroid response , red blood cell transfusion independence 4 6 month , overall survival time IPSS progression toxicity ( NCI-CTAE ) . The trial enroll 98 patient ( 49 patient per arm ) Treatment arm A : Azacitidine 75mg/sqm SQ per day 5 day every 28 day 6 course Dosing subsequent course adapt accord extrahematological toxicity cytopenia . In responder 6 course azacitidine accord IWG 2000 criterion ( minor major erythroid response HI-E ) 12 identical additional maintenance course deliver every 28 day , unless relapse occurs ( accord IWG 2000 criterion ) . Treatment arm B : • Azacitidine 75mg/sqm SQ per day 5 day every 28 day 6 course . ( dose subsequent course adapt accord extra hematological toxicity cytopenia ) AND • Epoetin beta : 60000U weekly SQ injection Dosing epoetin beta adapt accord current ASH-ASCO guideline black box warn epoetin beta . Epoetin beta therapy may therefore interrupt , case response azacitidine , soon hemoglobin level 12g/dl achieve two sequential bimonthly blood count measurement . A 40 % dose reduction epoetin beta require : - Hb level rise 1 g/dl observe within two week - Hb level exceed 11g/dl In responder 6 course azacitidine + epoetin beta , accord IWG 2000 criterion ( minor major erythroid response HI-E ) 12 identical additional maintenance course azacitidine deliver every 28 day , unless relapse occurs ( accord IWG 2000 criterion ) Epoetin beta administer describe . In arm , subsequent course deliver - In absence persistent grade &gt; 2 non-hematological toxicity - In absence rehospitalisation severe bleeding , infection febrile neutropenia non-hematological toxicity follow previous course - If neutrophil count &gt; 1G/l &gt; 50 % baseline neutrophil count - If platelet &gt; 75G/l &gt; 50 % baseline platelet count In case persistent cytopenia , blood count least checked every 2 week , next course delay resolution cytopenia , define . In case persistence cytopenia beyond day 56 precede course , new evaluation disease , use clinical examination , blood bone marrow examination +/- cytogenetics mandatory eventually pursue azacitidine lower dosing level .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>MDS define RCMD , RA without ring sideroblast RAEB 1 , CMML 1 , WBC &lt; 13 G /l accord WHO classification low int1 IPSS score AND primary secondary resistance epoetin alpha/ beta ( &gt; 60000 U/w ) darbepoetin ( &gt; 250ug/w ) , administer least 12 week requirement RBC transfusion &gt; 4 U previous 8 week Aged 18 year Adequate contraception , relevant Negative pregnancy test relevant Written Informed consent Ability participate clinical trial adhere study procedure Health insurance Therapyrelated MDS ( chemo radiotherapy previous neoplasm immune disorder ) Patients plan allogeneic bone marrow transplantation Creatininemia &gt; 1.5 upper normal value estimate Ccr le 30ml/mn ALAT ASAT &gt; 2.5 upper normal value Bilirubin &gt; 2N , except unconjugated hyperbilirubinemia due MDSrelated dyserythropoiesis Heart failure NYHA &gt; II Known allergy mannitol Other tumor , unstable last three year , except situ uterine carcinoma basal skin tumor ECOG &gt; 2 Life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
</DOC>